{
    "clinical_study": {
        "@rank": "20080", 
        "arm_group": [
            {
                "arm_group_label": "Rosuvastatin and Metformin SR, C001", 
                "arm_group_type": "Experimental", 
                "description": "Treatment Sequence 1(ABC)\nRosuvastatin 10mg and Metformin SR 500mg(Fed) ---> wash out ---> BCWP_C001(Fasted) ---> wash out ---> BCWP_C001(Fed)"
            }, 
            {
                "arm_group_label": "Treatment Sequence 2(ACB)", 
                "arm_group_type": "Experimental", 
                "description": "Rosuvastain 10mg and Metformin SR 500mg(Fed) ---> wash out ---> BCWP_C001(Fed) ---> wash out ---> BCWP_C001Fasted)"
            }, 
            {
                "arm_group_label": "Treatment Sequence 3(BAC)", 
                "arm_group_type": "Experimental", 
                "description": "BCWP_C001(Fasted) ---> wash out ---> Rosuvastain 10mg and Metformin SR 500mg(Fed) ---> wash out ---> BCWP_C001(fed)"
            }, 
            {
                "arm_group_label": "Treatment Sequence 4(BCA)", 
                "arm_group_type": "Experimental", 
                "description": "BCWP_C001(Fasted) ---> wash out ---> BCWP_C001(Fed) ---> wash out ---> Rosuvastain 10mg and Metformin SR 500mg(Fed)"
            }, 
            {
                "arm_group_label": "Treatment Sequence 5(CAB)", 
                "arm_group_type": "Experimental", 
                "description": "BCWP_C001(Fed) ---> wash out ---> Rosuvastain 10mg and Metformin SR 500mg(Fed) ---> wash out ---> BCWP_C001(Fasted)"
            }, 
            {
                "arm_group_label": "Treatment Sequence 6(CBA)", 
                "arm_group_type": "Experimental", 
                "description": "BCWP_C001(Fed) ---> wash out ---> BCWP_C001(Fasted) ---> wash out ---> Rosuvastain 10mg and Metformin SR 500mg(Fed)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the pharmacokinetic Profile and Safety/Tolerability\n      of BCWP_C001 compared to Co-Administration of Crestor 10mg and Glucophage XR 500mg, and to\n      evaluate the food effect of Pharmacokinetic profile of BCWP_C001 after administration."
        }, 
        "brief_title": "Evaluating of Pharmacokinetic Profile of BCWP_C001 and Co-administration of Rosuvastatin and Metformin", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Clinical Trials to Evaluate the Pharmacokinetic Profiles and Safety/Tolerability of\n      BCWP_C001 Formulation compared to Coadministration of Rosuvastatin and Metformin SR\n      Formulation, and to Evaluate the Effect of Food on the Pharmacokinetic Profile of BCWP_C001\n      after Single Oral Administration to Healthy Male Subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy Male Volunteer, age 20 to 45 years at the time of screening\n\n          -  Body weight is not less than 55kg, not more than 90kg and the result of Body Mass\n             Index(BMI) is not less than 18.5, not more than 25.0\n\n          -  Subject who has no congenital, chronic disease, and no disease symptom or finding in\n             medical examination result\n\n          -  Subject who is judged to be eligible by principal investigator or sub-investigator\n             according to various test results(clinical laboratory test, 12-lead ECG etc)\n\n          -  Subject who comprehended the purpose, contents of the study, property of clinical\n             drug and signed the informed consent to participate in the trial having the\n             willingness\n\n        Exclusion Criteria:\n\n          -  Subject who has history of hypersensitivity reaction for relevant drug(statin,\n             biguanide) or clinically significant hypersensitivity reaction\n\n          -  Subject who has history or presence of clinically disease in liver, kidney,\n             gastrointestinal tract, respiratory system, musculoskeletal, endocrine system, mental\n             disorder, blood-tumor, cardiovascular. Particulary, subject who has bleeding disorder\n             or tend to be bleeding with bruised easily\n\n          -  Subject who has family history of hereditary muscular disorder or muscular side\n             effect\n\n          -  Subject who has history of gastrointestinal tract disorder which can affect the drug\n             absorption or surgery(excluding appendectomy, hernia surgery)\n\n          -  Subject who had taken diagnosis with peptic ulcer within 2 month prior to the drug\n             administration\n\n          -  Subject who has results of clinical laboratory test as follows :\n\n        \u318dAST, ALT level exceed the normal range more than 1.5 times\n\n        \u318dTotal bilirubin level exceed the normal range more than 1.5 times\n\n          -  In the vital sign, systolic blood pressure is more than 150mmHg, less than 90mmHg or\n             diastolic blood pressure is more than 90mmHg, less than 60mmHg\n\n          -  Subject who has presence or history of drug abuse, or positive screening for drug\n             abuse\n\n             \u2192 Alcohol abuse defines to drink over 21 unit/week(alcohol 1unit = 10g = 12.5 mL)\n             persistingly\n\n          -  Subject who participated in another clinical trial within 3 month prior to the drug\n             administration\n\n          -  Subject who had taken medicine(Barbital etc) related drug metabolizing enzyme\n             induction or inhibition within 1 month prior to the drug administration\n\n          -  Subject who had taken prescription drug or oriental medicine within 2 weeks or OTC\n             drug or vitamin formulation within a week prior to the drug administration\n\n          -  Subject who had a diet which can affect the absorption, distribution, metabolism or\n             elimination of Rosuvastatin/Metformin (Particulary, Grapefruit - within 48h prior to\n             the drug administration)\n\n          -  Subject who donated whole blood within 2 month or component blood within 1 month\n             prior to the drug administration\n\n          -  Subject who smokes more than 10 cigarettes per day\n\n          -  Subject who has positive HBsAg, HCV Ab or HIV Ab\n\n          -  Subject who is judged to be ineligible by principal investigator or sub-investigator\n             according to various test results(clinical laboratory test, 12-lead ECG etc)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01992211", 
            "org_study_id": "BCWP1202_102"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Rosuvastatin and Metformin SR, C001", 
                    "Treatment Sequence 2(ACB)", 
                    "Treatment Sequence 3(BAC)", 
                    "Treatment Sequence 4(BCA)", 
                    "Treatment Sequence 5(CAB)", 
                    "Treatment Sequence 6(CBA)"
                ], 
                "description": "Co-administration of Rosuvastatin and Metformin SR", 
                "intervention_name": "Rosuvastatin and Metformin SR(Fed)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Crestor 10mg", 
                    "Glucophage XR 500mg"
                ]
            }, 
            {
                "arm_group_label": [
                    "Rosuvastatin and Metformin SR, C001", 
                    "Treatment Sequence 2(ACB)", 
                    "Treatment Sequence 3(BAC)", 
                    "Treatment Sequence 4(BCA)", 
                    "Treatment Sequence 5(CAB)", 
                    "Treatment Sequence 6(CBA)"
                ], 
                "description": "Combination of Rosuvastatin 10mg+Metformin SR 500mg (Fasted)", 
                "intervention_name": "BCWP_C001(Fasted)", 
                "intervention_type": "Drug", 
                "other_name": "BCWP_C001"
            }, 
            {
                "arm_group_label": [
                    "Rosuvastatin and Metformin SR, C001", 
                    "Treatment Sequence 2(ACB)", 
                    "Treatment Sequence 3(BAC)", 
                    "Treatment Sequence 4(BCA)", 
                    "Treatment Sequence 5(CAB)", 
                    "Treatment Sequence 6(CBA)"
                ], 
                "description": "Combination of Rosuvastatin 10mg+Metformin SR 500mg (Fed)", 
                "intervention_name": "BCWP_C001(Fed)", 
                "intervention_type": "Drug", 
                "other_name": "BCWP_C001"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Metformin", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 22, 2013", 
        "location": {
            "contact": {
                "email": "arpe00@snu.ac.kr", 
                "last_name": "Jangsoo Yoon, M.D.", 
                "phone": "82-2-2072-1666"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "investigator": {
                "last_name": "Kyung-Sang Yu, M.D. Ph.D", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "6", 
        "official_title": "Clinical Trials to Evaluate the Pharmacokinetic Profiles and Safety/Tolerability of BCWP_C001 Formulation Compared to Coadministration of Rosuvastatin and Metformin SR Formulation, and to Evaluate the Effect of Food on the Pharmacokinetic Profile of BCWP_C001 After Single Oral Administration to Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Kyung-Sang Yu, MD. PhD.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Rosuvastatin, Metformin Cmax, AUClast", 
            "safety_issue": "No", 
            "time_frame": "pre-dose, post-dose 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01992211"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "N-desmethyl rosuvastatin Cmax", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, post-dose 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72h"
            }, 
            {
                "measure": "N-desmethyl rosuvastatin AUClast", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, post-dose 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72h"
            }, 
            {
                "measure": "N-desmethyl rosuvastatin AUCinf", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, post-dose 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72h"
            }, 
            {
                "measure": "Rosuvastatin, N-desmethyl rosuvastatin, Metformin AUCinf", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, post-dose 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72h"
            }, 
            {
                "measure": "Rosuvastatin, N-desmethyl rosuvastatin, Metformin Tmax", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, post-dose 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72h"
            }, 
            {
                "measure": "Rosuvastatin, N-desmethyl rosuvastatin, Metformin t1/2", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, post-dose 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72h"
            }, 
            {
                "measure": "Rosuvastatin, N-desmethyl rosuvastatin, Metformin Vz/F", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, post-dose 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72h"
            }, 
            {
                "measure": "Rosuvastatin, N-desmethyl rosuvastatin, Metformin CL/F", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, post-dose 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72h"
            }
        ], 
        "source": "BC World Pharm Co. Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BC World Pharm Co. Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}